Chai collaborates with Bristol Myers Squibb
They advance AI-driven antibody discovery by leveraging Chai's molecular models to accelerate medicine development and bring new drugs to patients.
See the latest news and media coverage for Chai. We track all announcements, press releases, and industry mentions in real time, all in one place.
Artificial intelligence platform for computer-aided molecular design
chaidiscovery.comLast updated
In short: Chai Discovery secured $400 million in Series C funding and formed major AI drug discovery partnerships with BMS, Pfizer, and Novartis.
They advance AI-driven antibody discovery by leveraging Chai's molecular models to accelerate medicine development and bring new drugs to patients.
The round will advance AI-driven molecular design for drug discovery.
Novartis will use Chai's AI models to discover antibodies across multiple targets, building on prior technical engagement.
Led by General Catalyst and Oak HC/FT, with Thrive Capital, OpenAI, and others participating. Annie Lamont and Hemant Taneja join the board. Funds support research and team growth.
Bristol Myers Squibb (NYSE:BMY) announced a new collaboration with Chai Discovery to advance AI...
The fund-raising values the company at $3.8 billion and underscores investor interest in using artificial intelligence to ...
Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with ...
Chai Discovery, the AI company engineering models to discover new molecules, today announced that certain Chai Discovery frontier AI model capabilities will be made available...
Track Chai and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Chai and other trending companies.